-
Archives
- December 2017
- June 2017
- May 2017
- February 2017
- November 2016
- October 2016
- September 2016
- July 2016
- April 2016
- March 2016
- December 2015
- August 2015
- April 2015
- February 2015
- January 2015
- December 2014
- November 2014
- September 2014
- August 2014
- July 2014
- May 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
-
Meta
Tag Archives: value-based healthcare
AARP: Stakeholder for Waste and Moneyed Interests?
AARP, you lost whatever presumed credibility you thought you had with one article in the current issue of your magazine. I am talking about the hard copy of “All the President’s Scans: Our Commander in Chief Regularly Gets An Extensive … Continue reading
Posted in AARP
Tagged Executive physicals, misuse, overdiagnosis, overtreatment, overuse, premiums, stakeholders, value, value-based healthcare, waste
Comments Off on AARP: Stakeholder for Waste and Moneyed Interests?
Why Sanofi’s Zaltrap Deal Won’t Help Patients
I got excited when I read the New York Times story Nov. 9 (“Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection)”. Zaltrap is an intravenous infusion drug for metastatic colorectal cancer. It is used for advanced cancer that … Continue reading
Posted in Drug costs
Tagged colon cancer, copays, pharmaceutical companies, Sanofi, value-based healthcare, Zaltrap
1 Comment